Showing results (251-260 of 3,351) with videos related to

Sort By:
Pageof 336
The Lancet. Oncology|September 24, 2016
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trialRachel S Kerr, Sharon Love, Eva Segelov, et al.
The Lancet. Oncology|May 20, 2017
Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trialPrue C Allgood, Roberta Maroni, Sue Hudson, et al.
The Lancet. Oncology|June 25, 2017
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 studyAlexander E Perl, Jessica K Altman, Jorge Cortes, et al.
The Lancet. Oncology|June 9, 2017
Challenges behind proving efficacy of adjuvant chemotherapy after preoperative chemoradiation for rectal cancerCarlos Carvalho, Rob Glynne-Jones
The Lancet. Oncology|June 11, 2017
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trialDavid Cameron, James P Morden, Peter Canney, et al.
The Lancet. Oncology|February 5, 2010
Evidence-based organ-sparing radiotherapy in head and neck cancerPiet Dirix, Sandra Nuyts
The Lancet. Oncology|March 6, 2010
Minimally invasive surgery for head and neck cancerHood Keng Christopher Goh, Yuk Hui Ng, Dawn Tju Wei Teo
The Lancet. Oncology|March 6, 2010
Nerve-sparing and individually tailored surgery for cervical cancerLukas Rob, Michael Halaska, Helena Robova
The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.
The Lancet. Oncology|April 26, 2017
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trialRobert L Coleman, Mark F Brady, Thomas J Herzog, et al.
Pageof 336